Candoxatrilat. UK 73967.
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D010450:Endopeptidases / Q000378:metabolism*; D006333:Heart Failure / Q000188:drug therapy; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D018377:Neurotransmitter Agents / Q000037:antagonists & inhibitors*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D012076:Renal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D003509:Cyclohexanecarboxylic Acids; D015507:Drugs, Investigational; D018377:Neurotransmitter Agents; D011480:Protease Inhibitors; D012076:Renal Agents; C060942:candoxatrilat; D009320:Atrial Natriuretic Factor; D010450:Endopeptidases